16 September 2026 editorial review · Trial
NNC0363-1063: glucose-clamp study in type 1 diabetes: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: M–S
Outcome: Removed speculative strongest missing-datapoint claim; retained controlled clamp endpoint and no-results distinction.
Registry: NCT07305805. Endpoint reviewed: AUC, GIR,SS: Area under the glucose infusion rate-time curve at steady state (Visit 2 and 3: Day 2 and 3). Eligibility reviewed: Age 18 Years to 64 Years; diagnosis/stage, prior therapy and key biomarker criteria compared with site summary. Full exclusions remain in the registry. Literature access limit: No usable primary abstract was independently recovered for this record in this pass. Current registry protocol was the main source; detailed sponsor or conference data remain dependent on the cited source and were not fully reverified.